SAGE News and Press, Sage Therapeutics Inc. From 11/01/22

Sage Therapeutics (NASDAQ: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, today announced the appointment of Laura Gault, MD, Ph.D. as Chief Medical Officer. In her new role, Dr. Gault will focus on advancing Sage’s current and emer...

Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, announced today that it will host a live webcast on Tuesday, November 8, 2022 at 8:00 a.m. ET to review third quarter 2022 financial results and discuss recent...

Zuranolone 50 mg demonstrated a clinically meaningful and statistically significant improvement in depressive symptoms at Day 15, the primary endpoint, and at Days 3, 28, and 45, key secondary endpoints as previously reported Newly presented data offered additional insight into the ...

FN Media Group Presents Microsmallcap.com Market Commentary New York, NY – September 23, 2022 –  Canadian health insurers processed nearly $600 million in mental health service claims in 2021, up 75% from 2019 as more Canadians tapped into their me...

Sage Therapeutics, Inc. (Nasdaq: SAGE) and Biogen Inc. (Nasdaq: BIIB) today announced new analyses from across the development program for zuranolone, an investigational, oral, once-daily, 14-day treatment in clinical development for adult patients with major depressive disorder (MDD) a...

Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, announced today that the Company will present at the Morgan Stanley 20th Annual Global Healthcare Conference on Monday, September 12, 2022, at 3:40 p.m. ET in ...

Sage Therapeutics, Inc. (SAGE) Q2 2022 Earnings Conference Call August 2, 2022 8:00 AM ET Company Participants Helen Rubinstein - IR Barry Greene - CEO Albert Robichaud - Chief Scientific Officer Chris Benecchi - Chief Business Officer Kimi Iguchi - CFO ...

Sage Therapeutics press release ( NASDAQ: SAGE ): Q2 GAAP EPS of -$2.13 beats by $0.02 . Revenue of $1.5M (-8.5% Y/Y) misses by $0.27M . Cash Position: Cash, cash equivalents and marketable securities as of June 30, 2022 were $1.5 billion compared to $1.6 billi...

Rolling NDA submission for zuranolone in MDD and PPD remains on track, with completion expected in the second half of 2022 Announced positive topline data from the Phase 3 SKYLARK Study evaluating 50 mg zuranolone for PPD Enrolling multiple Phase 2 studies across neuro...

Sage Therapeutics ( NASDAQ: SAGE ) is scheduled to announce Q2 earnings results on Tuesday, August 2nd, before market open. EPS Estimate is -$2.15 (-17.5% Y/Y) and the consensus Revenue Estimate is $1.77M (+7.9% Y/Y). has beaten EPS estimates 50% of the time and has beaten...